Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond.
- Published In:
- Metabolism: clinical and experimental, 177, 156494 (2026)
- Authors:
- Muzurović, Emir, Katsiki, Niki, Volčanšek, Špela, Plescia, Fulvio, Rizzo, Manfredi, Mantzoros, Christos S
- Database ID:
- RPEP-15764
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15764APA
Muzurović, Emir; Katsiki, Niki; Volčanšek, Špela; Plescia, Fulvio; Rizzo, Manfredi; Mantzoros, Christos S. (2026). Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond.. Metabolism: clinical and experimental, 177, 156494. https://doi.org/10.1016/j.metabol.2026.156494
MLA
Muzurović, Emir, et al. "Emerging incretin- and multi-agonist-based treatments - the continued refinement and continuous expansion of a potent therapeutic armamentarium for cardio-kidney-liver-metabolic diseases and beyond.." Metabolism: clinical and experimental, 2026. https://doi.org/10.1016/j.metabol.2026.156494
RethinkPeptides
RethinkPeptides Research Database. "Emerging incretin- and multi-agonist-based treatments - the ..." RPEP-15764. Retrieved from https://rethinkpeptides.com/research/muzurovic-2026-emerging-incretin-and-multiagonistbased
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.